Status:
WITHDRAWN
Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate
Lead Sponsor:
Societe ACTIVBIOMAT
Conditions:
Hip Arthroplasty Replacement
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
The risk of infection after primary Total Hip Arthroplasties (THA)is generally estimated to be less than 1% but remains a severe and costly complication, source of morbidity and even mortality. The "b...
Eligibility Criteria
Inclusion
- Age less than 75 years old
- Aetiologies for THA : primary osteoarthritis, inflammatory diseases,Osteonecrosis
Exclusion
- Previous infectious hip arthritis
- Previous surgeries on the operated hip
- Revision of THA
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01454271
Last Update
August 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ambroise Paré Hospital. Orthopaedic surgery department
Boulogne-Billancourt, Île-de-France Region, France, 92100